174 related articles for article (PubMed ID: 27470571)
41. [Endothelin-1, angiotensin II and cancer].
Cazaubon S; Deshayes F; Couraud PO; Nahmias C
Med Sci (Paris); 2006 Apr; 22(4):416-22. PubMed ID: 16597412
[TBL] [Abstract][Full Text] [Related]
42. Regulation of endothelial proliferation by the renin-angiotensin system in human umbilical vein endothelial cells.
Herr D; Rodewald M; Fraser HM; Hack G; Konrad R; Kreienberg R; Wulff C
Reproduction; 2008 Jul; 136(1):125-30. PubMed ID: 18390690
[TBL] [Abstract][Full Text] [Related]
43. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
44. Hydroxysafflor yellow A inhibits angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NF-κB signaling pathway in H22 tumor-bearing mice.
Yang F; Li J; Zhu J; Wang D; Chen S; Bai X
Eur J Pharmacol; 2015 May; 754():105-14. PubMed ID: 25720342
[TBL] [Abstract][Full Text] [Related]
45. The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer.
Okazaki M; Fushida S; Harada S; Tsukada T; Kinoshita J; Oyama K; Tajima H; Ninomiya I; Fujimura T; Ohta T
Cancer Lett; 2014 Dec; 355(1):46-53. PubMed ID: 25224569
[TBL] [Abstract][Full Text] [Related]
46. Total alkaloids of Rubus alceifolius Poir inhibit tumor angiogenesis through suppression of the Notch signaling pathway in a mouse model of hepatocellular carcinoma.
Zhao J; Lin W; Cao Z; Zhuang Q; Zheng L; Peng J; Hong Z
Mol Med Rep; 2015 Jan; 11(1):357-61. PubMed ID: 25333354
[TBL] [Abstract][Full Text] [Related]
47. Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling.
Du N; Feng J; Hu LJ; Sun X; Sun HB; Zhao Y; Yang YP; Ren H
Oncol Rep; 2012 Jun; 27(6):1893-903. PubMed ID: 22426690
[TBL] [Abstract][Full Text] [Related]
48. Eupafolin Exhibits Potent Anti-Angiogenic and Antitumor Activity in Hepatocellular Carcinoma.
Jiang H; Wu D; Xu D; Yu H; Zhao Z; Ma D; Jin J
Int J Biol Sci; 2017; 13(6):701-711. PubMed ID: 28655996
[TBL] [Abstract][Full Text] [Related]
49. FGFR3 promotes angiogenesis-dependent metastasis of hepatocellular carcinoma via facilitating MCP-1-mediated vascular formation.
Liu X; Jing X; Cheng X; Ma D; Jin Z; Yang W; Qiu W
Med Oncol; 2016 May; 33(5):46. PubMed ID: 27044356
[TBL] [Abstract][Full Text] [Related]
50. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
[TBL] [Abstract][Full Text] [Related]
51. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.
El-Assal ON; Yamanoi A; Soda Y; Yamaguchi M; Igarashi M; Yamamoto A; Nabika T; Nagasue N
Hepatology; 1998 Jun; 27(6):1554-62. PubMed ID: 9620326
[TBL] [Abstract][Full Text] [Related]
52. [Effects of melittin on growth and angiogenesis of human hepatocellular carcinoma BEL-7402 cell xenografts in nude mice].
Song CC; Lu X; Cheng BB; DU J; Li B; Ling CQ
Ai Zheng; 2007 Dec; 26(12):1315-22. PubMed ID: 18076793
[TBL] [Abstract][Full Text] [Related]
53. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.
Chen ZY; Shi M; Peng LX; Wei W; Li XJ; Guo ZX; Li SH; Zhong C; Qian CN; Guo RP
J Transl Med; 2012 Dec; 10():245. PubMed ID: 23228017
[TBL] [Abstract][Full Text] [Related]
54. Antiangiogenic activity of vitexicarpine in experimentally induced hepatocellular carcinoma: Impact on vascular endothelial growth factor pathway.
Hassoun SM; Abdel-Rahman N; Eladl EI; El-Shishtawy MM
Tumour Biol; 2017 Jun; 39(6):1010428317707376. PubMed ID: 28651490
[TBL] [Abstract][Full Text] [Related]
55. Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammineplatinum-induced cytotoxicity in mouse xenograft model of bladder cancer.
Kosugi M; Miyajima A; Kikuchi E; Kosaka T; Horiguchi Y; Murai M; Oya M
Urology; 2009 Mar; 73(3):655-60. PubMed ID: 19167032
[TBL] [Abstract][Full Text] [Related]
56. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
Huynh H; Ong R; Soo KC
Angiogenesis; 2012 Mar; 15(1):59-70. PubMed ID: 22187171
[TBL] [Abstract][Full Text] [Related]
57. Chitosan nanoparticles inhibit the growth of human hepatocellular carcinoma xenografts through an antiangiogenic mechanism.
Xu Y; Wen Z; Xu Z
Anticancer Res; 2009 Dec; 29(12):5103-9. PubMed ID: 20044623
[TBL] [Abstract][Full Text] [Related]
58. Total alkaloids of Rubus alceifolius Poir shows anti-angiogenic activity in vivo and in vitro.
Zhao J; Lin W; Zhuang Q; Zhong X; Cao Z; Hong Z; Peng J
Integr Cancer Ther; 2014 Nov; 13(6):520-8. PubMed ID: 25148840
[TBL] [Abstract][Full Text] [Related]
59. Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model.
Raskopf E; Dzienisowicz C; Hilbert T; Rabe C; Leifeld L; Wernert N; Sauerbruch T; Prieto J; Qian C; Caselmann WH; Schmitz V
Hepatology; 2005 Jun; 41(6):1233-40. PubMed ID: 15915456
[TBL] [Abstract][Full Text] [Related]
60. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
